Wednesday, December 7, 2022 12/7/2022

Real-time tracking of virus evolution for vaccine strain selection and epidemiological investigation

Award Number: R35GM119774
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

Project Summary Viral pathogens are an enduring threat to global public health. This project aims to use viral genomic data to improve understanding of ongoing virus evolution and to make actionable inferences to reduce the global burden of viral infectious disease. In order to be relevant for public health interventions, analyses of viral sequence data need to be incredibly rapid, both in terms of computation and in terms of dissemination. To accomplish these goals, this project will create novel methodological tools to analyze evolutionary dynamics from in¿uenza genetic sequence data and to analyze transmission patterns from outbreak sequence data. Over the current project period (2016-2021), we developed a real-time analysis platform called Nextstrain, which provides up-to-date analyses for a variety of pathogens including in¿uenza virus, Ebola virus, Zika virus, dengue virus, mumps virus, tuberculosis and SARS-CoV-2. Bioinformatic pipelines developed through Nextstrain are reusable by academic groups and public health labs and resulting analyses are shareable via the website nextstrain.org. In the upcoming project period (2021-2026), we will re¿ne methods for forecasting strain dynamics of in¿uenza virus. Monitoring and forecasting evolution of viral strains is of paramount importance. New antigenic variants of in¿uenza that partially escape from prior human immunity emerge and rapidly sweep through the viral population. Such strains are less susceptible to vaccine-derived immunity and so antigenic evolution results in the need to frequently update the seasonal in¿uenza vaccine. This project aims to re¿ne methods to forecast strain dynamics and predict the makeup of the future in¿uenza population. This forecasting is especially relevant to in¿uenza vaccine strain selection, as a vaccine strain is chosen for the Northern Hemisphere in February for deployment the following winter. Accurate projections will aid in vaccine match for seasonal in¿uenza viruses and result in improved vaccine ef¿cacy. Technical innovations focus on extending models to work across different viruses, different gene segments and to incorporate spatial dynamics. In an outbreak scenario such as the West African Ebola epidemic, the American Zika epidemic or the SARS- CoV-2 pandemic, the focus of public health interventions focus on early diagnosis, contact tracing, isolation and treatment. Epidemiological understanding of transmission dynamics is of paramount importance to outbreak response. Viral genomic data can reveal otherwise hidden transmission patterns and aid in ef¿cient contact tracing. Geographic spread is especially amenable to genomic inferences. This project will develop tools to make epidemiological inferences from outbreak sequence data. These methods will continue to be deployed via the Nextstrain platform, allowing epidemiologists throughout the world to analyze their own datasets. Genomic epidemiology has the potential to truly inform outbreak response. Nextstrain has been instrumental to SARS-CoV-2 genomic epidemiology in the United States and world. Improvements to the accuracy and capabilities of the platform would be well placed.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2021	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Biomedical Research and Research Training	001	7	11/8/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$224,825
2023	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Biomedical Research and Research Training	000	6	11/8/2022	COMPETING CONTINUATION	-$224,825


Issue Date FY: 2022 ( Subtotal = $418,074 )
2022	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Biomedical Research and Research Training	004	8	8/22/2022	NON-COMPETING CONTINUATION	$418,074
2022	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Biomedical Research and Research Training	002	6	6/15/2022	COMPETING CONTINUATION	-$214,463
2022	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Biomedical Research and Research Training	001	6	11/6/2021	COMPETING CONTINUATION	$238,357
2022	2021	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Biomedical Research and Research Training	003	7	6/16/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$214,463
2022	2020	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Biomedical Research and Research Training	000	5	11/6/2021	NON-COMPETING CONTINUATION	-$238,357


Issue Date FY: 2021 ( Subtotal = $418,074 )
2021	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Biomedical Research and Research Training	000	6	4/23/2021	COMPETING CONTINUATION	$418,074


Issue Date FY: 2020 ( Subtotal = $401,525 )
2020	2020	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Biomedical Research and Research Training	000	5	5/12/2020	NON-COMPETING CONTINUATION	$401,525


Issue Date FY: 2019 ( Subtotal = $403,857 )
2019	2019	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Biomedical Research and Research Training	000	4	5/20/2019	NON-COMPETING CONTINUATION	$403,857


Issue Date FY: 2018 ( Subtotal = $406,123 )
2018	2018	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Biomedical Research and Research Training	000	3	5/29/2018	NON-COMPETING CONTINUATION	$406,123


Issue Date FY: 2017 ( Subtotal = $408,327 )
2017	2017	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Biomedical Research and Research Training	000	2	5/31/2017	NON-COMPETING CONTINUATION	$408,327


Issue Date FY: 2016 ( Subtotal = $410,473 )
2016	2016	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE NO J6-330	SEATTLE	WA	98109	KING	USA	Biomedical Research and Research Training	000	1	8/23/2016	NEW	$410,473


Grand Total All Awards = $2,866,453

Sum of Action Amount is $2,866,453;

Grand Total = $2,866,453

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Real-time tracking of virus evolution for vaccine strain selection and epidemiological investigation

Award Number: R35GM119774

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer